Peter Gottlieb, MD
Pulmonary Disease · Staten Island, NYNPI 1750320388
Payments from drug & device makers
Across 614 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca AB$7K
- AstraZeneca$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$1K
- Sanofi$667
- plus $3K from 33 others
What the payments were for
- Food & beverage$12,143100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca AB | 2 | $6,661 |
| AstraZeneca | 200 | $4,076 |
| GSK | 105 | $1,875 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,098 |
| Boehringer Ingelheim | 48 | $1,033 |
| Sanofi | 27 | $667 |
| Philips North America LLC | 33 | $632 |
| Pfizer | 17 | $361 |
| Amgen | 16 | $315 |
| Insmed, Inc. | 22 | $280 |
| Mylan Specialty L.p. | 9 | $169 |
| Jazz Pharmaceuticals Inc. | 8 | $163 |
| Baxter Healthcare | 8 | $160 |
| United Therapeutics Corporation | 7 | $144 |
| Optinose US, Inc. | 6 | $110 |
| Actelion Pharmaceuticals US, Inc. | 5 | $104 |
| Teva Pharmaceuticals USA, Inc. | 6 | $104 |
| Mallinckrodt Hospital Products Inc. | 6 | $95 |
| Electromed, Inc. | 8 | $82 |
| Verona Pharma, Inc. | 4 | $78 |
| Circassia Inc. | 3 | $57 |
| Melinta Therapeutics, LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Johnson & Johnson | 3 | $53 |
| Merck | 3 | $52 |
| AbbVie | 2 | $46 |
| Exact Sciences | 2 | $41 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Itamar Medical Inc | 1 | $25 |
| Boston Scientific | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| 3b Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,804 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 298 | $263,054 |
| Breo ElliptaFluticasone/Vilanterol | 181 | $88,687 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $80,548 |
| EliquisApixaban | 71 | $59,742 |
| Lactulose | 17 | $51,254 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $51,220 |
| Spiriva RespimatTiotropium Bromide | 71 | $50,025 |
| Dupixent SyringeDupilumab | 13 | $49,159 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 14 | $47,202 |
| JanuviaSitagliptin Phosphate | 35 | $40,182 |
| OzempicSemaglutide | 32 | $30,300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 838 | $23,779 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $23,076 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $22,466 |
| MounjaroTirzepatide | 17 | $22,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,875 | $429,822638 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,076 | $103,624190 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance, Combivent Respimat | $1,033 | $75,356104 claims |
| PfizerEliquis | $361 | $59,74271 claims |
| MerckJanuvia, Janumet | $52 | $52,60847 claims |
| Lilly USA, LLCMounjaro | $14 | $22,41917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Staten Island
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.